Navigation Links
Sales of Etimicin Sulfate to Expand Nationwide as Government Restriction is Lifted
Date:10/9/2007

SANTA MONICA, Calif., Oct. 9 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA), one of mainland China's leading pharmaceutical companies, today announced that the Chinese government has loosened national restrictions for the sale of Etimicin sulfate throughout China. Aida expects the sales of the Company's main revenue-generating product to increase noticeably as sales efforts are pursued nationwide without restriction.

The Ministry of Labor and Social Security eliminated restrictions on Etimicin, which is in the aminoglycoside antibiotic family. Aminoglycoside antibiotis were previously thought to be potentially unsafe for treating patients with a history of kidney disease. Although Etimicin had been clinically established to be safe and effective for people with such issues, it was not until now that the restrictions have been lifted.

Jin Biao, Chairman and CEO of Aida Pharmaceuticals, noted, "This is strong substantiation by the appropriate governmental regulatory body that the safeness of Etimicin has been universally and officially recognized. We are definitely pleased at this acceptance of the outstanding characteristic of low toxicity in this new generation of aminoglycoside antibiotics. We believe that this will allow us to promote the sales of Etimicin and broaden our customer base."

For more information about the lifting of the restriction for this particular type of drug please visit: http://www.molss.gov.cn/gb/ywzn/2007-06/20/content_183083.htm

About Etimicin Sulfate

Etimicin Sulfate is a new generation of the aminoglycoside family of antibiotics. Developed by Aida and its research partners, it is the first antibiotic developed in China. Aida has the exclusive right to the production and marketing of this powder and infusion type and is protected by patent through 2013. Etimicin sulfate is a semi-synthesized soluble antibiotic.

Researchers and doctors who performed the clinical tests believe that the product is a new generation of aminoglycoside antibiotics with high efficiency, safety and effectiveness to a broad spectrum of strains. Etimicin sulfate is suitable for the treatment of various inflammations, such as respiratory infections, kidney and urinogenital infections, soft skin tissue infection, as well as trauma and operation preventative uses.

About Aida

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices.


'/>"/>
SOURCE Aida Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Jellyfish partners for sales tracking technology
2. Doyle wants sales tax applied to digital downloads
3. Mortgagebot builds online sales even as housing declines
4. Third Wave reports another loss, stronger sales
5. Johnson Controls reports record quarterly sales
6. Can sales outsourcing grow Wisconsin biotechs?
7. Sonic Foundry reports quarterly loss, higher Mediasite sales
8. My-oh, its BIO! Where sales hype and science collide
9. Third Wave shuffles finance, sales management
10. Johnson Controls sales up, profits down
11. Turning ads into sales: Context is king
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... The American Medical Informatics ... of the National Coordinator for Health IT (ONC) outlining a measurement approach to ... were available when and where it was needed. The organization of health informatics ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... and traumatic injuries, will be accelerated by research at Worcester Polytechnic Institute (WPI) ... of wound healing and tissue regeneration. , The novel method, developed by WPI ...
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® Media has released ... and Beyond. The paper outlines the key trends that are creating both opportunities ... witnessed a lot of highs and lows as the precision agriculture market has ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman Prizes. ... are given in two categories, one for experiment and the other for theory ...
Breaking Biology Technology:
(Date:3/14/2016)... NXTD ) ("NXT-ID" or the "Company"), a company ... of a new series of commercials on Time Warner Cable ... .  The commercials will air on Bloomberg TV, Fox Business ... show. --> NXTD ) ("NXT-ID" or the "Company"), ... the airing of a new series of commercials on Time ...
(Date:3/10/2016)... India , March 10, 2016 ... a new market research report "Identity and Access Management ... & Audit, Compliance, and Governance), by Organization Size, by ... to 2020", published by MarketsandMarkets, The market is estimated ... USD 12.78 Billion by 2020, at a Compound Annual ...
(Date:3/9/2016)... March 9, 2016  Crossmatch ® , a ... solutions, today announced the addition of smart features ... multi-factor authentication platform. New contextual and application-specific ... step-up security where it,s needed most — while ... DC . --> Washington, ...
Breaking Biology News(10 mins):